Hemophilia is a rare disorder that is complex to diagnose and to manage. These evidence-based guidelines offer practical recommendations on the diagnosis and general management of hemophilia, as well as the management of complications including musculoskeletal issues, inhibitors, and transfusion-transmitted infections. By compiling these guidelines, the World Federation of Hemophilia aims to assist healthcare providers seeking to initiate and/or maintain hemophilia care programs, encourage practice harmonization around the world and, where recommendations lack adequate evidence, stimulate appropriate studies.

/pdf/guidelines-for-the-management-of-hemophilia-1x6t2d999b.pdf

Guidelines for the management of hemophilia.

WFH Guidelines for the Management of Hemophilia, 3rd edition

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.12672

Definitions in hemophilia: communication from the SSC of the ISTH.

https://www.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1538-7836.2011.04214.x

A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

Robert Prejs

Papers

The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia.